title: Lonidamine in advanced colorectal cancer: a phase II study of the Italian Oncology Group for Clinical Research (GOIRC).
abstract: Twenty-one patients with metastatic colorectal adenocarcinoma, all previously treated with chemotherapy for metastatic disease, were treated with lonidamine (LDN). The major toxicity encountered was muscular (myalgias in 48%) and gastro-intestinal (nausea and/or vomiting in 52%). Other toxicities included abdominal pain, somnolence, fever, arthralgia and ototoxicity. In the 14 patients evaluable for response we observed no complete or partial remission, 8 stable disease and 6 progressive disease. LND has no clinically worthwhile activity against colorectal carcinoma refractory to conventional chemotherapy.
authors.affiliation: Medical Oncology Service, Ospedale Maggiore, Parma, Italy.
authors.forename: R
authors.initials: R
authors.lastname: Passalacqua
authors.forename: G
authors.initials: G
authors.lastname: Bisagni
authors.forename: M
authors.initials: M
authors.lastname: Bertusi
authors.forename: D
authors.initials: D
authors.lastname: Donati
authors.forename: F
authors.initials: F
authors.lastname: Buzzi
authors.forename: F
authors.initials: F
authors.lastname: Di Costanzo
authors.forename: C
authors.initials: C
authors.lastname: Basurto
authors.forename: S
authors.initials: S
authors.lastname: Gori
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000473:pathology; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007191:Indazoles / Q000009:adverse effects / Q000627:therapeutic use*; D007558:Italy; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D011720:Pyrazoles / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D007191:Indazoles; D011720:Pyrazoles; C016371:lonidamine